February 3, 2015 — Scientists are working to develop breakthrough therapies for pancreatic cancer, one of the deadliest cancers affecting both men and women.
Pancreatic cancer is a disease that frequently presents no symptoms until it reaches very advanced stages. Surgery is the only chance for a cure, but most patients are not surgical candidates because of the location of the tumor in the pancreas or because the cancer has spread. Moreover, most people who undergo surgery relapse and subsequently die of pancreatic cancer.
The U.S. Food and Drug Administration (FDA) has approved three treatments in the past 20 years for advanced pancreatic cancer to help patients live longer: (1) gemcitabine; (2) erlotinib in combination with gemcitabine; and (3) nab-paclitaxel in combination with gemcitabine.
“Today we know more about this form of cancer. We know it usually starts in the pancreatic ducts and that the KRAS gene is mutated in tumor samples from most patients with pancreatic cancer,” says Abhilasha Nair, M.D., an oncologist on the FDA team that works on cancers of the digestive system, including the stomach, pancreas and colon.
Pancreatic cancer is the fourth leading cause of cancer death in the United States. Yearly, about 46,420 people will be diagnosed with the disease and 39,590 will die from it, according to the National Cancer Institute.
This cancer accounts for less than 3 percent of new cancer diagnoses each year, but it is aggressive and deadly. The five-year survival rate is only about 5 percent. If untreated, patients can die quickly, Nair says. Treatments include chemotherapy and, for some patients, surgery and/or radiation therapy.
Scientists are researching how certain factors increase the risk for pancreatic cancer. They include smoking, pancreatitis, longstanding diabetes, genetic changes (BRCA1 and BRCA2 mutations) and Lynch syndrome (an inherited disorder that increases the risk for certain cancers).
Scientists continue to work on developing drugs that target the KRAS mutation found in pancreatic tumors. “Getting the right drug to target the right mutation would be a big break for treating patients with pancreatic cancer,” Nair says. “KRAS is a very evasive target. We need to learn more about it so we can better understand how to overcome it.”
To achieve that, scientists are digging deep into the cells of tumors to learn why pancreatic cancer is resistant to most available chemotherapy drugs.
“Something in the extracellular matrix may be preventing the tumor cells from being affected by chemotherapy,” Nair says. Much of the research focuses on the tumor’s environment, identifying ways to overcome the tumor’s defenses and improving the delivery of chemotherapy directly to cancer cells.
Researchers are also exploring immune therapies, which have been successful in treating melanoma and other cancers. With immune therapy, doctors could improve the patient’s own defenses against the cancer.
“Not too long ago, the prognosis for melanoma patients was very poor. But with the advent of these new therapies that boost the patient’s own immune system, the landscape has greatly improved,” Nair says. “We hope that new research in pancreatic cancer will ultimately give us a similar if not better outcome in the fight against this aggressive cancer.”
For more information: www.fda.gov
April 17, 2024 
